General Fluidics

About General Fluidics

General Fluidics, founded in 2013 by Kenneth Kotz, is a US-based company that is pioneering a new category of blood-testing technology with its Axess diagnostic platform.

Kenneth Kotz, who has a background in mechanical engineering and has conducted extensive research in microfluidics and diagnostic technologies, co-founded the company to address the limitations of traditional blood testing. His expertise has been pivotal in the development of the company's core technology.

The company's flagship product, the Axess platform, is an in-vitro diagnostic tool that integrates three advanced analytical technologies: hematology, clinical chemistry, and immunoassays. This integration allows for a broad range of blood and urine tests to be performed at the point of care, providing clinicians with comprehensive diagnostic information from a single platform. The Axess platform is designed to make high-quality blood diagnostics more accessible and efficient.

General Fluidics operates in the in-vitro diagnostics market, serving healthcare providers such as clinics and hospitals. The business model is centered on the sale of the Axess platform and the recurring revenue from the consumables required for the tests. The company aims to improve patient outcomes by enabling faster and more comprehensive diagnostic testing outside of traditional laboratory settings.